{{Drugbox
| verifiedrevid = 408966679
| IUPAC_name = ''N''-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide
| image = Tolazamide.svg
| image2 = Tolazamide ball-and-stick.png
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|tolazamide}}
| MedlinePlus = a682482
| licence_US = Tolazamide
| pregnancy_AU = C
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = ?
| metabolism = metabolized in the liver to active metabolites
| elimination_half-life = 7 hours
| excretion = [[Kidney|Renal]] (85%) and fecal (7%)
<!--Identifiers-->
| IUPHAR_ligand = 6847
| CAS_number = 1156-19-0
| ATC_prefix = A10
| ATC_suffix = BB05
| PubChem = 5503
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00839
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5302
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9LT1BRO48Q
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00379
| ChEBI = 9613
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 817
<!--Chemical data-->
| C=14 | H=21 | N=3 | O=3 | S=1
| molecular_weight = 311.401 g/mol
| SMILES = O=S(=O)(c1ccc(cc1)C)NC(=O)NN2CCCCCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OUDSBRTVNLOZBN-UHFFFAOYSA-N
}}

'''Tolazamide''' is an [[Wiktionary:oral|oral]] [[blood glucose]] lowering [[medication|drug]] used for people with [[Type 2 diabetes]]. It is part of the [[sulfonylurea (medicine)|sulfonylurea]] family (ATC A10BB).

==Synthesis==
[[para-toluenesulfonamide|''para''-Toluenesulfonamide]] is converted to its [[carbamate]] with [[ethyl chloroformate]] in the presence of a base. Heating that intermediate with [[azepane]] leads to the displacement of the ethoxy group and the formation of tolazemide:<ref>{{cite journal |author1=Wright, J. B. |author2=Willette, R. E. | journal = J. Med. Chem. | year = 1962 | volume = 5 | pages = 815–822 | doi = 10.1021/jm01239a016 | issue = 4}}</ref>

[[File:Tolazamide synthesis.png|700px|center|thumb|Tolazemide synthesis:<ref>{{Cite journal
 | pmid = 14056414
| year = 1962
| author1 = Wright
| first1 = J. B.
| title = Antidiabetic Agents. N4-Arylsulfonylsemicarbazides
| journal = Journal of Medicinal and Pharmaceutical Chemistry
| volume = 91
| pages = 815–22
| last2 = Willette
| first2 = R. E.
}}</ref> {{US patent|3063903}} {{Cite patent|GB|887886}} {{Cite patent|DE|1196200}}]]

==References==
{{reflist}}

==External links==
* [http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682482.html NIH/Medline]

{{Oral hypoglycemics}}
{{Ion channel modulators}}

[[Category:Potassium channel blockers]]
[[Category:Sulfonylureas]]
[[Category:Azepanes]]


{{gastrointestinal-drug-stub}}